Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial

被引：0
|
作者：
Li Zhang
Xin Mei
Zhigang Hu
Bo Yu
Chaoyang Zhang
Yong Li
Kaitai Liu
Xuejun Ma
Jinli Ma
Xingxing Chen
Jin Meng
Wei Shi
Xiaofang Wang
Miao Mo
Zhimin Shao
Zhen Zhang
Xiaoli Yu
Xiaomao Guo
Zhaozhi Yang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Radiation Oncology
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] Shanghai Key Laboratory of Radiation Oncology,Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine
[4] University of Science and Technology of China,Department of Radiotherapy
[5] the Affiliated Jiangyin Hospital of Nantong University,Department of Radiation Oncology
[6] The First Hospital of Quanzhou Affiliated to Fujian Medical University,Department of Oncology
[7] Guizhou Provincial People’s Hospital,Department of Radiation Oncology
[8] The Affiliated Lihuili Hospital of Ningbo University,Department of Cancer Prevention & Clinical Statistics Center
[9] Fudan University Shanghai Cancer Center,Department of Breast Surgery
[10] Fudan University Shanghai Cancer Center,Key Laboratory of Breast Cancer in Shanghai
[11] Fudan University Shanghai Cancer Center,Department of Medical Oncology
[12] Kashgar Prefecture Second People ’ s Hospital,undefined
[13] Xinjiang Uyghur Autonomous Region,undefined
来源：
BMC Cancer | / 24卷
关键词：
Breast cancer; Supraclavicular nodal irradiation; Target volume; Survival outcome; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial
    Huijbers, Anouck
    van Pelt, Gabi W.
    Kerr, Rachel S.
    Johnstone, Elaine C.
    Tollenaar, Rob A. E. M.
    Kerr, David J.
    Mesker, Wilma E.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (05) : 1043 - 1048
  • [42] Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater
    Neoptolemos, J. P.
    Moore, M. J.
    Cox, T. F.
    Valle, J. W.
    Palmer, D. H.
    Mcdonald, A.
    Carter, R.
    Tebbutt, N. C.
    Dervenis, C.
    Smith, D.
    Glimelius, B.
    Coxon, F. Y.
    Lacaine, F.
    Middleton, M. R.
    Ghaneh, P.
    Bassi, C.
    Halloran, C.
    Olah, A.
    Rawcliffe, C. L.
    Buechler, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [43] Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2-3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    Guo, Shan-Shan
    Li, Xiao-Yun
    Liu, Li-Ting
    Jia, Guo-Dong
    Liu, Sai Lan
    Sun, Xue-Song
    Lv, Xing
    Xiang, Yan-Qun
    Luo, Dong-Hua
    Sun, Rui
    Qi, Yang
    Liu, Qing
    Li, Ji-Bin
    Mo, Hao-Yuan
    Guo, Ling
    Zhao, Chong
    Guo, Xiang
    Tang, Lin-Quan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial
    Sunami, Eiji
    Kusumoto, Tetsuya
    Ota, Mitsuyoshi
    Sakamoto, Yoshiyuki
    Yoshida, Kazuhiro
    Tomita, Naohiro
    Maeda, Atsuyuki
    Teshima, Jin
    Okabe, Michio
    Tanaka, Chihiro
    Yamauchi, Junichiro
    Itabashi, Michio
    Kotake, Kenjiro
    Takahashi, Keiichi
    Baba, Hideo
    Boku, Narikazu
    Aiba, Keisuke
    Ishiguro, Megumi
    Morita, Satoshi
    Takenaka, Naruhito
    Okude, Ryota
    Sugihara, Kenichi
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 22 - +
  • [45] Adjuvant chemotherapy guided by an integrated mRNA-lncRNA signature in triple-negative breast cancer (BCTOP-T-A01): A randomized, open-label, multicenter phase 3 trial
    He, Min
    Jiang, Yi-Zhou
    Gong, Yue
    Fan, Lei
    Liu, Xi-Yu
    Zeng, Xiao-Hua
    Fu, De-Yuan
    Song, Chuan-Gui
    Zhuang, Zhi-Gang
    Wu, Ke-Jin
    Wang, Jie
    Wang, Zhonghua
    Shao, Zhi-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater
    Neoptolemos, J. P.
    Moore, M. J.
    Cox, T. F.
    Valle, J. W.
    Palmer, D. H.
    Mcdonald, A.
    Carter, R.
    Tebbutt, N. C.
    Dervenis, C.
    Smith, D.
    Glimelius, B.
    Coxon, F. Y.
    Lacaine, F.
    Middleton, M. R.
    Ghaneh, P.
    Bassi, C.
    Halloran, C.
    Olah, A.
    Rawcliffe, C. L.
    Buechler, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
    Hurvitz, Sara A.
    Bosserman, Linda D.
    Chan, David
    Hagenstad, Christopher T.
    Kass, Frederick C.
    Smith, Frederick P.
    Rodriguez, Gladys I.
    Childs, Barrett H.
    Slamon, Dennis J.
    SPRINGERPLUS, 2014, 3 : 1 - 9
  • [48] Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial
    Lestingi, Jean F. P.
    Guglielmetti, Giuliano B.
    Trinh, Quoc-Dien
    Coelho, Rafael F.
    Pontes, Jose Jr Jr
    Bastos, Diogo A.
    Cordeiro, Mauricio D.
    Sarkis, Alvaro S.
    Faraj, Sheila F.
    Mitre, Anuar, I
    Srougi, Miguel
    Nahas, William C.
    EUROPEAN UROLOGY, 2021, 79 (05) : 595 - 604
  • [49] PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.
    Kim, Gun Min
    Jeung, Hei-Cheul
    Jung, Kyung Hae
    Kim, Se Hyun
    Kim, Han Jo
    Lee, Ki Hyeong
    Park, Kyong Hwa
    Lee, Ji Eun
    Ahn, Mi Sun
    Kohn, Sujin
    Lee, Sung Sook
    Moon, Yong Wha
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    C. Ola Landgren
    Ajai Chari
    Yael C. Cohen
    Andrew Spencer
    Peter Voorhees
    Jane A. Estell
    Irwindeep Sandhu
    Matthew W. Jenner
    Catherine Williams
    Michele Cavo
    Niels W. C. J. van de Donk
    Meral Beksac
    Philippe Moreau
    Hartmut Goldschmidt
    Steven Kuppens
    Rajesh Bandekar
    Pamela L. Clemens
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Craig C. Hofmeister
    Leukemia, 2020, 34 : 1840 - 1852
12345